Novel 1,3,4-thiadiazole-chalcone hybrids containing catechol moiety: synthesis, antioxidant activity, cytotoxicity and DNA interaction studies by Jakovljević, Katarina et al.
This is an Accepted Manuscript, which has been through the  
Royal Society of Chemistry peer review process and has been 
accepted for publication.
Accepted Manuscripts are published online shortly after 
acceptance, before technical editing, formatting and proof reading. 
Using this free service, authors can make their results available 
to the community, in citable form, before we publish the edited 
article. We will replace this Accepted Manuscript with the edited 
and formatted Advance Article as soon as it is available.
You can find more information about Accepted Manuscripts in the 
author guidelines.
Please note that technical editing may introduce minor changes 
to the text and/or graphics, which may alter content. The journal’s 
standard Terms & Conditions and the ethical guidelines, outlined 
in our author and reviewer resource centre, still apply. In no 
event shall the Royal Society of Chemistry be held responsible 
for any errors or omissions in this Accepted Manuscript or any 
consequences arising from the use of any information it contains. 
Accepted Manuscript
rsc.li/medchemcomm
www.rsc.org/medchemcomm
 ISSN 2040-2503
 MedChemComm
 Broadening the field of opportunity for medicinal chemists
Themed issue: Antibiotic Resistance
Volume 7 Number 1 January 2016 Pages 1–204
 MedChemComm
 Broadening the field of opportunity for medicinal chemists
View Article Online
View Journal
This article can be cited before page numbers have been issued, to do this please use:  K. Jakovljevic, M.
Joksovic, I. Z. Mati, N. Petrovic, T. Stanojkovic, D. Sladi, M. Vujcic, B. Janovic, L. Joksovic, S. Trifunovic
and V. Markovi, Med. Chem. Commun., 2018, DOI: 10.1039/C8MD00316E.
1 
 
Novel 1,3,4-thiadiazole-chalcone hybrids containing catechol moiety: 
Synthesis, antioxidant activity, cytotoxicity and DNA interaction studies 
 
 
Katarina Jakovljević,a Milan D. Joksović,a Ivana Z. Matić,b Nina Petrović,b,c Tatjana 
Stanojković,b Dušan Sladić,d  Miroslava Vujčić,
e
 Barbara Janović,
e Ljubinka Joksović,a 
Snežana Trifunovićd and Violeta Marković*a 
 
 
a
 Faculty of Science, Department of Chemistry, University of Kragujevac,  R. Domanovica 12, 34000     
  Kragujevac, Serbia 
 
b Institute of Oncology and Radiology of  Serbia, Pasterova 14, 11000 Belgrade, Serbia 
c Laboratory for Radiobiology and Molecular Genetics, “Vinča” Institute of  Nuclear Sciences, University of 
Belgrade, 11000 Belgrade, Serbia 
 
d
 Faculty of Chemistry, University of Belgrade, Studentski trg 16,  11000 Belgrade, Serbia 
 
e Institute for Chemistry, Technology and Metallurgy, Njegoševa 12, 11000 Belgrade, Serbia 
 
Abstract Hybrid compounds that combine 1,3,4-thiadiazole containing catechol moiety with chalcone motif 
have been synthesized and examined for their antioxidant activity, cytotoxicity and DNA-binding activity. The 
series of thirteen compounds showed strong antioxidant and cytotoxic effects on human acute promyelocytic 
leukemia HL-60 cells. Several compounds exerted good cytotoxic activities on cervical adenocarcinoma HeLa 
cells. The treatment of HeLa cells with IC50 and double IC50 concentrations of the compounds 5a, 5c, 5f and 5m 
induced statistically significant increase in the percentage of cells within subG1 cell cycle phase. The examined 
compounds caused G2/M cell cycle arrest in HeLa cells. Each of these compounds triggered apoptosis in HeLa 
cells through activation of caspase-3, the main effector caspase, caspase-8, which is involved in the extrinsic 
apoptotic pathway, and caspase-9, which is involved in the intrinsic apoptotic pathway. All of the examined 
compounds decreased the expression levels of MMP2 in HeLa cells and levels of protumorigenic miR-133b. 
Compounds 5a and 5m lowered the expression level of oncogenic miR-21 in HeLa cells.  In addition, 
compounds 5a, 5f and 5m decreased the expression levels of oncogenic miR-155 while the treatment of HeLa 
cells with compounds 5a, 5c and 5f increased expression of tumor-suppressive miR-206. The observed effects 
of the compounds on expression levels of four examined miRNAs suggest their prominent cancer-suppressive 
activity. The investigation by absorption and fluorescence spectroscopy showed more efficient calf thymus 
DNA binding activity of the compound 5m in comparison to other tested compounds. Results of pUC19 
plasmid cleavage study and comet assay showed DNA damaging activities of compounds 5a and 5c.  
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1. Introduction 
 
Anticancer hybrid molecules incorporate two or more different, covalently linked   
pharmacophores with ability to modulate multiple biological targets and improve therapeutic potential 
of the designed compounds in comparison to single bioactive precursors. Using molecular 
hybridization techniques, it is possible to synthesize numerous hybrids based on known anticancer 
scaffolds leading to a more favorable pharmacological profile than the sum of each individual 
compounds.1 Chalcones are frequently selected as one of privilege structures because of their 
significant anticancer properties and facile preparation, offering major advancements in the field of 
hybrid molecules.2,3 Such chalcone hybrid analogues with promising anticancer activity have already 
been synthesized by the coupling of chalcones with various bioactive compounds including 
coumarin,4,5 1,2,3-triazole,6 retinoid,7 naphthoquinone,8 β-carboline,9 artemisinin,10 N-4-piperazinyl-
ciprofloxacin,11 anthraquinone, 12 pyrazole-5-carboxamide,13 thiazole14 and isoxazole.15  
We selected 1,3,4-thiadiazole as a second bioactive compound for combining with chalcone 
unit to generate a new hybrid molecule suitable to simultaneously target several pathogenic 
mechanisms. The covalent bond was established by formation of an amide in the reaction of amine 
group of heterocycle and previously transformed carboxylic function into acid chloride of chalcone 
analogue. 1,3,4-Thiadiazoles exhibited a wide spectrum of anticancer activities owing to high 
electron-donating ability of nitrogen atoms to form hydrogen bonds or to coordinate metal ions.16,17 
Although 1,3,4-thiadiazoles have a promising anticancer potential, their toxicity still remains a major 
concern.18 Molecular hybridization may be a way to enhance activity or selectivity and also, overcome 
the side effects associated with the single compound. 
It is well known that antioxidants (including phenolic ones) block free radicals to induce 
damage of biological macromolecules under oxidative stress, preventing their oxidation, DNA 
mutations and malignant changes.19 Very recently, we combined bioactive functions of 1,3,4-
thiadiazole and phenolic acid moiety to obtain novel conjugates with antioxidant  and antiproliferative 
activity.20 The reported antiproliferative activities of 1,3,4-thiadiazoles and chalcone analogues, as 
well as radical scavenging properties of phenolic compounds, led us to rational design and synthesis 
of new molecular hybrids with evaluation of their antioxidant, cytotoxic and DNA-binding potential. 
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2. Results and Discussion 
 
2.1. Chemistry 
 
The novel 1,3,4-thiadiazole-chalcone hybrids were synthesized in three steps (Scheme 1). 
Initially, chalcone analogues 4a-m were prepared using the Claisen-Schmidt condensation of 4-
formylbenzoic acid 3 with various substituted acetophenones in the presence of NaOH, according to 
slightly modified literature procedure.21 Subsequently, chalcones 4a-m were converted into acyl 
chloride by action of SOCl2 and, without isolation, reacted with 4-(5-amino-1,3,4-thiadiazol-2-
yl)benzene-1,2-diol 2 in dioxane giving the final hybrid compounds 5a-m in moderate to good yields 
(53-87%). Previously, thiadiazole derivative was synthesized by the reaction of 3,4-dihydroxybenzoic 
acid and thiosemicarbazide in phosphoryl chloride.20 Although acid chlorides are very reactive 
compounds, the formation of an amide requires long time and high temperature due to poor 
nucleophilicity of amino group of 1,3,4-thiadiazole. Almost all compounds still contained a 
significant amount of dioxane. The solvent was eliminated by dissolving crude product in DMF or 
DMSO and subsequent precipitation with water or by complete evaporation of THF solutions. The 
structure of all compounds was confirmed by means of 1H and 13C NMR spectroscopy (see 
Supplementary content), IR and elemental analysis. The olefinic protons of the chalcone double bond 
in hybrid compounds 5a-m, as well as their corresponding precursors 4a-m, appeared as an AB 
system. On the basis of coupling constant values (J = 15.6−16.0 Hz), the compounds 5a, 5c, 5d, 5f, 
5g, and 5i-m were isolated and characterized in E-isomeric form. However, the compounds 5b, 5e 
and 5h, and their chalcone precursors (4b, 4e and 4h) having the coupling constant values in the range 
from 7.0 to 8.2 Hz correspond to the less stable Z-configuration.22 This kind of geometry of the 
chalcone double bond is not very frequent and since these derivatives contain an ortho-substituted 
acetophenone moiety in their structure, it is probable that Z-isomeric form is favored due to the steric 
factors. Aromatic protons corresponding to the phenolic group appeared in the range of 6.86-7.44 
ppm, giving a doublet for H-5, doublet of doublets for H-6 and another doublet for H-2. Protons 
belonging to the benzoic acid moiety were well resolved in the form of the AB system for most of the 
thiadiazole-chalcone derivatives. 
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Scheme 1. Reagents and conditions: a) POCl3, rt, H2NHNC(=S)NH2, 1h, reflux; b) substituted 
acetophenones, NaOH, MeOH, 2h, reflux, HCl; c) SOCl2, DMF, CH2Cl2, 2h, rt; d) 2, dioxane, 12h, 
reflux. 
 
 
2.2. Biology 
 
2.2.1. Radical scavenging activity and effects of pretreatment of HeLa cells with 
1,3,4-thiadiazole-chalcone hybrids on ROS levels 
 
Antioxidant activity of phenolic acids has been well known because of their preventive effect 
on malignant changes that are associated with radical species.23 Reactive oxygen species (ROS) in the 
form of free radicals (superoxide and hydroxyl radical) and neutral molecules (H2O2) have been 
neutralized by stable phenolic antioxidants, diminishing DNA damaging and cancer formation.19 
Thus, the compounds showing antioxidant and cytotoxic activity have a great importance and a 
combination of phenolic antioxidant moiety with other bioactive pharmacophores could be a good 
way to obtain more potent radical scavengers as a result of their synergistic effects.  
Generally, all synthesized hybrid molecules exhibited better DPPH radical scavenging 
activity than referent ascorbic acid (Table 1).  
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Table 1. DPPH scavenging activity of the 1,3,4-thiadiazole-chalcone hybrids 5a-m.a 
Compound IC50 ± SD (µM) 
5a 12.03 ± 0.50 
5b 11.66 ± 0.41 
5c 17.17 ± 0.38 
5d 11.81 ± 0.31 
5e 9.76 ± 0.75 
5f 10.33 ± 0.30 
5g 17.86 ± 0.03 
5h 13.91 ± 0.32 
5i 17.82 ± 0.65 
5j 18.04 ± 0.23 
5k 14.01 ± 0.34 
5l 13.45 ± 0.09 
5m 11.06 ± 0.24 
Ascorbic acid 20.23 ± 0.14 
a Results are mean values ± SD from three measurements. 
 
 Unfortunately, all our compounds were practically insoluble in methanol, a common solvent 
for DPPH test, and determination of radical scavenging activity was performed in diluted dimethyl 
sulfoxide. However, DMSO was found to considerably decrease antiradical capacity of ascorbic acid 
due to the formation of a molecular complex with DMSO through intermolecular hydrogen bonds.24 
Also, dramatic solvent effects were established on the rates of H-abstraction from phenolic 
compounds.25 In accordance with these facts, in separate experiments we observed significantly lower 
scavenging activity at higher concentrations of DMSO, suggesting the formation of a molecular 
complex between DMSO and our compounds. From this reason we were not able to consider the 
influence of chalcone moiety with various electron donating or withdrawing substituents and make a 
comparison with other 1,3,4-thiazole compounds containing phenolic hydroxyl groups. Anyway, the 
potent radical scavenging potential of our compounds is evident, and for that reason we decided to 
explore their effects on ROS levels in human cervical adenocarcinoma HeLa cells. We examined the 
effects of four compounds – 5a, 5c, 5f and 5m, which were selected for all further analyses due to 
their prominent cytotoxic activity and good selectivity in the antiproliferative action (Table 2). As it 
could be seen in Fig. 1 A, significant accumulation of ROS in the H2O2-treated cells indicates 
activation of endogenous ROS production by added H2O2. The pretreatment of HeLa cells with 
subtoxic IC20 concentrations of 5a and 5f for 24 h (10 µM for each compound) slightly increased the 
ROS levels induced by H2O2, while pretreatment with compounds 5c and 5m did not affect the ROS 
levels triggered by H2O2. The radical species (phenoxyl radical etc.) produced by the oxidation of 5a 
and 5f with H2O2 are highly reactive and subject to further oxidation giving quinone compounds. 
Quinones are still reactive and can be stabilized by interaction with nucleic acid.26 This reaction might 
be responsible for the toxic pro-oxidant effect of 5a and 5f which may damage cellular constituents 
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like DNA by induction of oxidative cytotoxic stress in cancer cells, activating programmed cell death 
– apoptosis.  
In the absence of exogenously added H2O2, the intracellular ROS levels in HeLa cells treated 
for 24 h with each of the four compounds were decreased when compared with basal ROS levels in 
control. This behavior of all tested compounds, especially 5c, is a result of their radical scavenging 
potential to neutralize basal ROS in HeLa cells (Fig. 1, B). Some cancer cells, in advanced stage of 
disease, have adapted to oxidative stress due to their antioxidative defense capacity. Therefore, the 
cancer cells show resistance to the drugs that induce intracellular ROS production, such as paclitaxel 
or doxorubicin.27 Thus, possibility of drugs to reduce antioxidant system in combination with oxidant 
agents might be useful in antitumor therapies. A redox modulation of ROS level by production of 
sufficient amount of ROS provoking apoptosis or by decrease in antioxidant level could be a good 
way to kill cancer cells which are more sensitive to exogenous oxidative stress than normal cells.    
 
 
 
Fig. 1. Effects of 24 h pretreatment of HeLa cells with IC20 concentrations of the 1,3,4-thiadiazole-
chalcone hybrids 5a, 5c, 5f and 5m (10 µM for each compound) on ROS generation induced by 
hydrogen peroxide (10 mM) (A) and endogenous ROS levels (B). The results are presented as the 
mean ± SD of two independent experiments. 
 
 
2.2.2.  Cytotoxic activity 
 
The cytotoxicity of 1,3,4-thiadiazole-chalcone hybrids containing antioxidant catechol moiety 
was evaluated against three human malignant cell lines (cervical carcinoma HeLa, acute 
promyelocytic leukemia HL-60, and lung carcinoma A549), and normal human lung fibroblasts 
MRC-5 using MTT cell survival test. The obtained IC50 values are shown in Table 2. Generally, all 
tested compounds exerted the strongest cytotoxic activity against leukemia HL-60 cells with IC50 
values in the range from 6.92 µM to 16.35 µM. The compounds 5a, 5f, 5h, 5l and 5m also showed 
strong cytotoxic effects on HeLa cells, with IC50 values from 9.12 µM to 12.72 µM. Lung carcinoma 
A549 cells were the least sensitive to the cytotoxic activity of the examined hybrids, while other 
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tested derivatives exerted moderate to low cytotoxic activity. As it can be seen in Table 2, there is no 
significant difference between the influence of electron-donating and electron-withdrawing groups of 
the acetophenone moiety on the cytotoxic action against cancer cells. This indicates that the 
thiadiazole-chalcone pharmacophore present in the structure of the tested compounds has the crucial 
role in their antiproliferative action. All of the compounds from this series exerted two to four times 
higher cytotoxic activity against HeLa and HL-60 malignant cell lines in comparison to their activity 
against normal MRC-5 cells, with the exception of 5g, 5j and 5k against HeLa cells. In addition, all 
tested derivatives showed lower toxicity against normal MRC-5 cells comparing to cisplatin as a 
referent chemotherapeutic.  
 
Table 2. The cytotoxic activity of the investigated 1,3,4-thiadiazole-chalcone hybrids containing 
antioxidant phenolic moiety.a 
Compd. 
IC50±SD (µM) 
HeLa HL-60 A549 MRC-5 
5a 9.37±0.86 8.40±1.44 42.75±2.77 36.00±1.10 
5b 9.12±1.19 7.62±1.40 21.80±2.55 18.56±2.25 
5c 9.63±1.26 8.39±1.39 27.87±4.05 34.25±4.88 
5d 11.20±2.32 8.44±1.52 26.35±1.90 33.72±3.35 
5e 10.22±0.73 11.97±1.27 50.23±5.35 48.01±6.43 
5f 9.98±0.99 9.92±0.50 92.14±6.64 42.54±3.88 
5g 57.55±7.58 16.35±0.87 89.10±9.35 81.33±9.25 
5h 11.08±2.10 8.88±1.32 46.89±1.71 39.58±4.82 
5i 17.75±0.17 10.63±0.96 89.33±2.99 45.81±3.38 
5j 40.22±3.64 9.74±1.54 87.74±6.82 38.24±4.95 
5k 54.76±2.77 11.17±0.52 127.75±8.37 39.44±3.49 
5l 11.04±2.41 6.92±0.53 23.23±1.37 21.17±1.23 
5m 12.72±3.24 15.72±1.66 47.85±1.92 68.52±7.69 
cisplatin 4.91±0.74 2.88±0.34 13.21±0.89 9.35±1.29 
a Results are mean values ± SD of three independent experiments. 
 
 
 
2.2.3.  Effects of the 1,3,4-thiadiazole-chalcone hybrids on cell cycle phase 
distribution  
 
With the aim to investigate the mechanisms of the cytotoxic activity of four selected 1,3,4-
thiadiazole-chalcone hybrids 5a, 5c, 5f and 5m, the changes in cell cycle phase distribution of cervical 
adenocarcinoma HeLa cells treated with IC50 and 2IC50 concentrations of these compounds for 24 h 
were assessed. The incubation with both tested concentrations of the compounds induced statistically 
significant increase in the percentage of HeLa cells within subG1 phase when compared with 
untreated, control cell samples (Fig. 2). These results point to ability of the examined compounds to 
induce cell death in HeLa cells. Furthermore, compound 5c applied at IC50 concentration and 
compound 5m applied at double IC50 concentration caused significant increase in the percentage of 
cells within G2/M cell cycle phase in comparison to those percentages in the control cells. The 
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incubation of HeLa cells with double IC50 concentrations of the compounds 5a, 5c and 5f also led to 
accumulation of cells in G2/M phase, although those differences were not statistically significant. The 
obtained data demonstrate that tested compounds cause G2/M cell cycle arrest in HeLa cells, thus 
preventing cell entry into mitosis and eventually leading to cell apoptosis. The double IC50 
concentrations of compounds 5a and 5m, as well as IC50 and double IC50 concentrations of compound 
5c, induced significant decrease in the percentage of treated cells within G1 phase when compared 
with control cells, suggesting enhanced sensitivity of cells within G1 phase to the cytotoxic action of 
these compounds. Our findings are in accordance with literature data showing that compounds 
bearing chalcone bioactive scaffold induce G2/M cell cycle arrest and apoptotic cell death in cancer 
cells.28 
 
Fig. 2. Changes in the cell cycle phase distribution of human cervical carcinoma HeLa cells treated 
with IC50 (A) and 2IC50 concentrations (B) of the 1,3,4-thiadiazole-chalcone hybrids 5a, 5c, 5f and 5 
m after 24 h treatment. The results are presented as the mean ± SD of three independent experiments. 
Statistically significant differences between control and treated cell samples are marked with * 
(p<0.05). 
 
2.2.4.  Effects of the specific caspase inhibitors 
 
To further examine whether the tested compounds could induce apoptotic cell death in treated 
HeLa cells, the cells were pretreated with specific peptide inhibitors of caspase-3, caspase-8 or 
caspase-9 two hours before addition of compounds and their effects were determined by cell cycle 
analysis.  As it could be seen in Fig. 3, the notable decrease in the percentage of HeLa cells within 
subG1 cell cycle phase was observed in cell samples which were pretreated with caspase-3 inhibitor, 
caspase-8 inhibitor or caspase-9 inhibitor, and afterwards exposed to compounds 5a, 5c, 5f or 5m 
when compared with HeLa cell samples which were not pretreated with inhibitors before addition of 
the compound. The obtained results indicate that examined 1,3,4-thiadiazole-chalcone hybrids (5a, 5c, 
5f and 5m) trigger apoptosis in HeLa cells through the activation of main effector caspase-3, 
activation of caspase-8, implicated in extrinsic pathway of apoptosis and caspase-9, implicated in 
intrinsic pathway of apoptosis.  
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Fig. 3. Effects of the specific caspase inhibitors (Z-DEVD-FMK - caspase-3 inhibitor, Z-IETD-FMK 
-caspase-8 inhibitor, Z-LEHD-FMK - caspase-9 inhibitor) on the percentages of HeLa cells within 
subG1 phase treated with 2IC50 concentrations of the compounds 5a  (A), 5c (B),  5f (C), and 5m (D). 
Representative graphs are shown. 
 
 
2.2.5. Effects of 1,3,4-thiadiazole-chalcone hybrids on gene and microRNA expression 
levels 
 
Increased levels of matrix-metalloproteinase-2 (MMP2), matrix-metalloproteinase-9 (MMP9), 
and vascular endothelial growth factor A (VEGFA), and increased levels of typical oncogenic 
miRNAs (miR-21 and miR-155) overexpressed in various cancer types,29 and decreased levels of 
matrix-metalloproteinase inhibitor 3 (TIMP3)30 are associated with the cell growth, migration, 
epithelial mesenchymal transition, invasion, metastasis, and angiogenesis.31 MiR-133b was known to 
be downregulated in prostate cancer, but this microRNA exerted protumorigenic activity in cervical 
cancer.32 MiR-206 is described to be downregulated in cervical cancer,33 and that overexpression 
induces apoptosis.34 
     To further elucidate the molecular mechanisms of cytotoxic activity of our compounds, we 
examined changes in the expression levels of extracellular matrix-degrading proteases MMP2 and 
MMP9, TIMP3 which inhibits matrix metalloproteinases and regulates proteolysis of extracellular 
matrix, as well as in the expression of inducer of angiogenesis VEGFA, and several microRNAs-miR-
21/133b/155/206 in human cervical adenocarcinoma HeLa cells treated with subtoxic IC20 
concentrations of the examined compounds (Fig. 4).  
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Fig. 4. Changes in expression levels of MMP2 gene(A), MMP9 gene (B), TIMP3 gene (C), VEGFA 
gene (D), miR-21 (E), miR-133b (F), miR-155 (G) and miR-206 (H) in HeLa cells exposed to 
subtoxic IC20 concentrations of the compounds 5a, 5c, 5f and 5 m (10 µM for each compound) for 24 
h. Representative graphs are shown. 
 
All of the examined compounds (5a, 5c, 5f, and 5m) decreased expression levels of MMP2 
and TIMP3, but increased expression levels of MMP9, when compared with those levels in untreated, 
control HeLa cells. In addition, compound 5a slightly increased the VEGFA expression level in HeLa 
cells, while compounds 5f and 5m slightly decreased the expression of VEGFA in these cells. The 
observed downregulation of VEGFA expression in HeLa cells and inhibition of formation of tubular 
structures by EA.hy926 cells exerted by compounds 5f and 5m indicate the mild antiangiogenic 
activities of these compounds (Fig. 5).  
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Fig. 5. Photomicrographs of control EA.hy926 cells and EA.hy926 cells incubated with subtoxic IC20 
concentrations of the compounds 5a, 5c, 5f (6.5 µM for each compound) and 5m (8 µM) for 20 h. 
 
     The ability of the examined 1,3,4-thiadiazole-chalcone hybrids to downregulate expression levels 
of MMP2 in HeLa cells might suggest their suppressive effects on cervical cancer cell invasion and 
establishment of metastasis. The investigation of Kato et al. suggested that expression levels of 
MMP2 may be closely associated with invasion ability of cervical cancer cells.35 We observed that all 
tested compounds remarkably increased MMP9 expression levels in HeLa cells. MMP9 is connected 
with increased invasion and metastasis, but besides this protumorigenic role, there is experimental 
evidence that MMP9 may exert protective effects on cancer progression and metastasis in addition to 
anti-angiogenic effect.36,37 The study in a mouse model of multistage skin carcinogenesis caused by 
HPV16 oncogene demonstrated that MMP9 deficient transgenic mice had decreased proliferation rate 
of keratinocytes and a lower incidence of invasive tumors, which had more aggressive phenotype, 
while mice expressing MMP9 developed a larger number of tumors, which had less aggressive 
phenotype.37 Furthermore, MMP9 may suppress further progression of malignant tumors through 
generation of various anti-angiogenic peptides, such as angiostatin and tumstatin.36 Taken together, 
these findings might suggest that upregulation of MMP9 expression levels in tumor stroma which 
could be induced by our compounds, might contribute to suppression of tumor growth and 
progression. 
     Considering the effects of the compounds on microRNA expression levels in HeLa cells, the 
compound 5a decreased levels of three crucial oncogenic miRNAs-miR-21/155 and protumorigenic 
miR-133b in cervical cancer, while it slightly increased level of tumor suppressive miR-206, when 
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compared with those levels measured in control cells.  The compound 5c remarkably increased 
expression levels of miR-206 and miR-155 in comparison to control HeLa cells, and decreased 
expression of protumorigenic miR-133b. Treatment with compounds 5c and 5f caused mild increase 
in miR-21 expression in HeLa cells. Exposure to compound 5f caused decrease in the expression of 
miR-133b and miR-155 in addition to increase in the expression level of miR-206. The compound 5m 
lowered the expression levels of all four examined miRNAs when compared with controls cells. Our 
research showed that compounds 5a and 5m induced remarkable decrease in the expression level of 
oncogenic miR-21, that could result in reduced proliferation, migration and invasion of cervical 
carcinoma cells. These tumor-suppressive effects had shown to be regulated through phosphatase and 
tensin homolog (PTEN).38 The antiproliferative potential of our four compounds is further proved by 
their ability to reduce levels of oncogenic miR-133b, which had been reported to be involved in 
enhanced proliferation and colony formation of cervical cancer cells, as well as in further progression 
and metastasis of cervical cancers, affecting AKT1 and ERK signaling pathways.39 Moreover, the 
compounds 5a, 5f and 5m lowered the expression levels of miR-155, which is overexpressed in 
cervical cancer tissue, stimulates cell proliferation and exerts oncogenic activity, confirming their 
cancer-suppressive properties.40 The pro-apoptotic effects of compounds 5a, 5c and 5f could be, at 
least in part, attributed to the increased expression of tumor-suppressor miR-206 in treated HeLa cells. 
The miR-206 had been reported as an inducer of apoptosis in HeLa cells, that was associated with 
inhibition of neurogenic locus notch homolog protein 3 (Notch 3).34 
     The investigated compounds and miRNAs changed the examined gene expression levels. TIMP3 is 
a proven target of miR-21, MMP9 is a target of miR-133b, while VEGF mRNA is target of miR-206 
according to TargetScan Human 7.0 (http://www.targetscan.org/).41  
 
2.2.6. DNA binding study 
 
As it is well known, the interaction of DNA with a small molecule can give rise to changes in 
the absorbance and in the peak position in the absorption spectra. Hyperchromism and hypochromism 
are regarded as spectral evidence for DNA double-helix structural change when DNA reacts with 
other molecules. Hyperchromism originates from the disruption of the DNA duplex secondary 
structure and is indicative of the partial or non-intercalative modes42 and hypochromism originates 
from the stabilization of the DNA duplex by either the intercalation binding mode or the electrostatic 
effect of small molecules.43,44 Electronic absorption spectra of biologically most active 1,3,4-
thiadiazole–chalcone hybrids recorded at different concentrations without or with fixed concentration 
of CT-DNA are shown in Fig. 6A. UV–vis spectra of all compounds displayed similar absorption 
bands. It was found that the maximum absorption of 5a, 5c, 5f and 5m was centered at 309 nm, 310 
nm, 305 nm and 323 nm, respectively. Upon interaction with CT-DNA, the formation of a 
compound─CT-DNA occured with no shift of absorption maximum at 259 nm. Detailed absorption 
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changes induced by binding of the compounds to CT-DNA were further calculated from the 
experimental data, Fig. 6B. The value of the sum of absorbances at 259 nm of a free compound and 
free CT-DNA was a different from the absorption value of a compound─CT-DNA. 
 
 
Fig. 6A.  Changes in UV–Vis absorption spectra of CT-DNA (95 µM) after interaction with different 
concentrations of 1,3,4-thiadiazole-chalcone hybrids. Panels A, B, C and D: UV–Vis absorption 
spectra of 5a (10µM, 20µM and 40µM), 5c (10µM, 20µM and 40µM), 5f (10µM, 20µM and 40µM) 
and 5m (10µM, 20µM and 40µM), respectively before and after interaction with CT-DNA.  
 
Fig. 6B.  Changes in UV–Vis absorption spectra of CT-DNA (95 µM) after interaction with different 
concentrations of 1,3,4-thiadiazole-chalcone hybrids. Panels E, F, G and H: comparison of absorption 
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at 259 nm between the CT-DNA─1,3,4-thiadiazole–chalcone compounds and the sum values of CT-
DNA and 1,3,4-thiadiazole–chalcone compounds. The representative absorption assay curves are 
shown. Triplicate assays were applied to all compounds and control CT-DNA.  
 
The hypochromism of about 13% was observed with lower concentrations of 5a, Fig. 6B 
(Panel E) while the decrease in absorption intensity at 259 nm was less pronounced at higher 
concentrations. In case of 5c, Fig. 6B (Panel F) the hyperchromism was observed (-13.7%, -7.36% 
and -4.9% at 10 µM, 20 µM and 40 µM, respectively) and with 5m, Fig. 6B (Panel H), 
hyperchromism was also observed, more pronounced at lower concentrations probably. The DNA 
showed the least changes after interaction with 5f, Fig. 6B (Panel G) (this weak hypochromism was 
calculated as 2.4% at the lowest concentration of the compound). Previous studies demonstrated that a 
significant hypochromic effect with a concomitant red shift upon ligand binding to DNA was the 
typical characteristic of the intercalating mode.45,46 In this work, the obtained hypochromic effects of 
5a and 5f and hyperchromic effects of 5c and 5m with no red shift probably reflect changes in the 
conformation and structure of CT-DNA upon binding of the compounds in the minor groove, via 
formation of hydrogen bonds between hydroxyl groups of 1,3,4-thiadiazole─chalcone parts of the 
compounds and exposed AT base pairs.  
The stability of binding between CT-DNA and 1,3,4-thiadiazole–chalcone compounds was 
determined by a spectroscopic titration. Absorption spectra of 5a, 5c, 5f and 5m without and with CT-
DNA at different concentrations are shown in Fig. 7, Panels A – D). The absorbance at 259 nm was 
monitored for each concentration of DNA (insets in Fig. 7, show plots after linearization). Binding 
constant Kb of 5a, 5c, 5f and 5m were calculated using equation (2) and values of 1.09×10
3 M−1, 
0.74×103 M−1, 0.71×103 M−1 and 1.01×103 M−1, respectively, are obtained. These values are 
comparable with ones previously published for anthraquinone-chalcone hybrids12 and other 
structurally different compounds.47,48 However, relatively low correlation coefficients, indicate low 
binding strength of interaction of 1,3,4-thiadiazole-chalcone hybrids with helix of CT-DNA. 
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Fig. 7. The representative absorption titration curves of 5a (A), 5c (B), 5f (C) and 5m (D) at fixed 
concentration (40 µM) with increasing concentrations of CT-DNA (2.2, 4.4, 6.6, 8.8, 11 and 13 × 10–5 
M); Insets: determination of binding constant (Kb) by plot of [DNA]/(εa – εf) vs. [DNA]; The arrow 
show the changes in absorbance upon increasing amounts of CT-DNA. Triplicate assays were applied 
to all compounds and control CT-DNA.  
 
 
In order to provide additional insight into the interactions between the DNA and 1,3,4-
thiadiazole─chalcone hybrids, the study with the minor groove binder Hoechst 33258 was performed. 
Hoechst 33258 (H) binds strongly and selectively with high affinity to double-stranded B-DNA 
structure and like other minor groove binders, it recognizes at least four AT base pairs. It binds by 
combination of hydrogen bonding, van der Waals contacts with the walls of the minor groove, and 
electrostatic interactions between its cationic structure and the DNA.49 Binding of Hoechst 33258 to 
CT-DNA was followed by excitation at 350 nm with maximum in fluorescence at 444 nm. The 
fluorescence intensity of the band at 444 nm of the Hoechst−CT-DNA system decreased remarkably 
with the increasing concentration of the compounds (Fig. 8). The fluorescence intensities of H−CT-
DNA−compound system were 58%, 60%, 55% and 51% of H−CT-DNA system at maximal applied 
concentration of 5a, 5c, 5f and 5m, respectively. The observed reduction of fluorescence indicated the 
propensity of the 1,3,4-thiadiazole–chalcone hybrids to bind to DNA minor groove. Insets in Fig. 8 
show the quenching plots demonstrating that quenching of H bound to CT-DNA by these compounds 
are in agreement with the linear Stern-Volmer Eq. (3) for the investigated concentration ranges of the 
compounds. The corresponding quenching constants of H−CT-DNA system for 5a, 5c, 5f and 5m 
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were calculated by linear regression of the plot I0/I versus [compound]/[CT-DNA] as K = 3.30, 2.95, 
3.95 and 4.66, respectively.  
 
 
Fig. 8. Displacement of DNA-bound Hoechst 33258 (H) by 5a (A), 5c (B), 5f (C) and 5m (D). 
Emission spectra (λex = 350 nm) of H (2.8 x 10
-5 M) bound to CT-DNA (1 x 10-4 M, top line) and 
quenching of H—CT-DNA system by the compounds at increasing concentrations (0 – 2.2 x 10-5 M, 
curves from top to bottom). Insets: Fluorescence curves of EB bound to CT-DNA at λmax = 444 nm by 
1,3,4-thiadiazole-chalcone compounds; r = [compound]/[CT-DNA]. The arrow shows that 
fluorescence intensity decreased with increasing concentration of the complex. The representative 
fluorescence assay curves are shown. Triplicate assays were applied to all compounds and control CT-
DNA.  
 
 
Comparing K values for the quenching fluorescence intensity obtained by the displacement 
experiments, it may be concluded that 5m with thiophene ring was more efficient as a groove binder 
than other tested 1,3,4-thiadiazole–chalcone hybrids with benzene rings. However, considering the 
extent of the interaction of the compounds with CT-DNA, it can be concluded that these compounds 
binds to DNA exhibiting minor groove mode with low binding strength, Also, the results suggested 
that the differences in benzoic moiety contribute to binding, as well as the binding in the groove most 
likely occurs via forming hydrogen bonds among hydroxyl groups of 1,3,4-thiadiazole─chalcone 
parts of the compounds and exposed AT base pairs.  
 
2.2.7. Comet assay 
Comet assay50 is a versatile and sensitive method for measuring DNA damage in terms of 
single and double-strand breaks in DNA. In order to evaluate the extent of DNA damage induced by 
selected compounds comet assay was performed on MRC-5 cells which were treated for 24h with 
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different concentration of compounds 5a, 5c, 5f and 5m. From the results presented in Fig. 9 it can be 
seen that the compounds caused DNA damage, evidenced by the increase in % of DNA in the comet 
tail. Each of the tested compounds exhibited as concentration-dependent DNA damage in MRC-5 
cells. At the highest concentration tested (25 µM) DNA damage detected was 45% in case of 5a 
compound, while in the case of 5c DNA damage was 38%. Lower degree of DNA damage was 
detected in case of compounds 5m and 5f, 25% and 20%, respectively.  
 
Fig. 9. Detection of DNA damage (% tail DNA) using the Comet assay with MRC-5 cells after 24h 
exposure with compounds 5f, 5m, 5a and 5c (3.125 – 25 µM). PBS was used as negative control, and 
H2O2 (50 µM, 5min in-gel exposure) was used as positive control. The y-axis shows the mean ± SD of 
DNA damage measured through tail intensity parameter. The experiments were conducted in triplicate 
and repeated twice. 
 
2.2.8. pUC19 DNA cleavage study 
 
Since a weak DNA damaging activity was defected in cell culture, the abilities of most potent 
1,3,4-thiadiazole–chalcone hybrids to cleave double-stranded plasmid DNA were investigated using 
an agarose electrophoretic assay and DMSO as solvent of compounds in the performed range of 
concentration (from 0.5 – 20%) had no effects on conformation of plasmid DNA (results not shown). 
As shown by a representative agarose gel electrophoresis in Fig. 10 (A), lane 1, control plasmid 
pUC19 consisted mainly of supercoiled form FI and nicked form FII, with also a small quantity of 
linear form FIII. All of the compounds were tested and the results showed that there were no 
significant changes in band mobility, and no strand scission under applied range of concentrations. In 
Fig. 10 (A) results obtained with compound 5a are shown. Very similar results were obtained with 
compounds 5c, 5f and 5m (not shown). Further, strand scission was tested under reducing conditions, 
in presence of iron(II). Iron(II) per se is involved in the damage of DNA51 the results of cleavage 
pUC19 by iron(II) shown in Fig. 10 (B), lanes P+Fe(II) (1:1) and P+Fe(II) (1:2). When the compound 
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and iron were used in mole ratio 1:1, (Fig. 10 (B), lanes P+5a+Fe(II) (1:1), P+5cFe(II) (1:1), 
P+5f+Fe(II) (1:1) and P+5m+Fe(II) (1:1)) and mole ratio 1:2 ((Fig. 10 (B), lanes P+5a+Fe(II) (1:2), 
P+5cFe(II) (1:2), P+5f+Fe(II) (1:2) and P+5m+Fe(II) (1:2)), 1,3,4-thiadiazole–chalcone hybrids 
abolished the effects of iron, probably by complex formation and/or by anti-oxidative action of 
catechol moiety. Iron Fe(III) had no effect under any conditions, Fig. 10 (B), lanes P+5m+Fe(III) 
(1:2) and P+Fe(III) (1:2). These results indicate that DNA cleavage could not be the cause of 
cytotoxicity. The obtained protective activities of 1,3,4-thiadiazole–chalcone hybrids are comparable 
to those published for anthraquinone-chalcone hybrids.12 
 
 
Fig. 10. The representative agarose gel electrophoresis of plasmid pUC19 treated with 1,3,4-
thiadiazole–chalcone hybrid: (A) plasmid pUC19 (12 nM) without (lane P) and with 5a at 
concentration of 0.05 mM, 0.1 mM, 0.15 mM, 0.2 mM, 0.25 mM, 0.3 mM and 0.4 mM, lanes 1, 2, 3, 
4, 5, 6, and 7, respectively; (B) effects of 5a, 5c, 5f and 5m on Fe(II) induced pUC19 damage with 
compound–iron mole ratio 1:1 and 1:2.  
 
 
3. Conclusion 
 
Combining two pharmacophores, 1,3,4-thiadiazole derived from protocatechuic acid with 
antioxidant properties and a series of chalcones, thirteen novel hybrid compounds were prepared and 
evaluated for radical scavenging, cytotoxic and DNA-binding potential. The synthesized 1,3,4-
thiadiazole-chalcone hybrids containing phenolic moiety exerted a strong antioxidant and moderate to 
good cytotoxic activity against HL-60 and HeLa cells. The selected compounds 5a, 5c, 5f and 5m 
caused G2/M cell cycle arrest in HeLa cells and showed the ability to trigger apoptosis in HeLa cells 
through activation of caspase-3, caspase-8, and caspase-9. All examined compounds remarkably 
downregulated the expression levels of MMP2 in treated HeLa cells, suggesting their suppressive 
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effects on cervical cancer cell invasion and metastasis. The compounds 5a and 5m induced 
remarkable decrease in the expression level of oncogenic miR-21 in HeLa cells while all four 
examined compounds lowered levels of protumorigenic miR-133b.  In addition, the compounds 5a, 5f 
and 5m decreased the expression levels of oncogenic miR-155. The treatment of HeLa cells with 
compounds 5a, 5c and 5f elevated expression of tumor-suppressor miR-206. These effects of 
compounds on expression levels of four examined miRNAs point to their prominent cancer-
suppressive properties. 1,3,4-Thiadiazole-chalcone hybrids bind weakly to the helix of CT-DNA in 
the minor groove, induce weak DNA damage in cell culture, and protect plasmid DNA from iron(II)–
induced DNA damage, but DNA displacement of fluorescent probes and plasmid DNA damage 
activity as well as damage DNA by comet assay indicated their DNA damaging potential. Taken 
together, the results of our research indicate the promising antiproliferative properties of four newly 
synthesized 1,3,4-thiadiazole-chalcone hybrids containing phenolic moiety. 
 
 
4. Experimental section 
 
4.1. Chemistry 
 
4.1.1. Physical measurements and methods  
 
 Melting points were determined on a Mel-Temp capillary melting points apparatus, model 
1001 and are uncorrected. Elemental (C, H, N, S) analysis of the samples was carried out in the 
Center for Instrumental Analysis, Faculty of Chemistry, Belgrade. UV spectra were recorded using an 
Agilent Technologies, Cary 300 Series UV-Vis Spectrophotometer. IR spectra were obtained on a 
Perkin Elmer Spectrum One FT-IR spectrometer with a KBr disc. 1H and 13C-NMR spectra were 
taken on a Varian Gemini 200 MHz spectrometer.  
 
4.1.2. Procedure for the preparation of 5a-m 
 
Procedure for the synthesis of 2. A mixture of 3,4-dihydroxybenzoic acid, 1 (2.00 mmol, 
0.308 g,) and POCl3 (1.0 mL) was stirred for 20 minutes at the room temperature. Then, 
thiosemicarbazide (2.50 mmol, 0.228 g) was added and the resulting suspension was refluxed for 1 
hour. After cooling the flask in an ice bath, 3.0 ml of distilled water was added carefully, and reflux 
was continued for 1 hour. The mixture was then cooled to the room temperature, saturated aqueous 
solution of NaOH was added until pH 8.5 was reached and the suspension was stirred for 1 hour at the 
room temperature. The formed precipitate of the corresponding 1,3,4-thiadiazole derivative (2) was 
then filtrated, dried over CaCl2 and recrystallized from hot 50 % aqueous EtOH. 
Procedure for the synthesis of 4. A mixture of 4-formylbenzoic acid (2.3 mmol, 0.345 g), a 
corresponding substituted acetophenone (2.00 mmol) and solid NaOH (4.6 mmol, 0.184 g) in dry 
methanol (10.0 ml) was refluxed for 2 hours. After completion, the mixture was cooled to the room 
temperature, 5.0 ml of distilled water was added and pH of the solution was adjusted to 4.5 with HCl 
aqueous solution (2 M), upon which a precipitate was formed. The precipitate (4a-m) was stirred for 
30 minutes and then subsequently collected by suction filtration, dried over CaCl2 and recrystallized 
from hot MeOH. 
Procedure for the synthesis of 5a-m. To the mixture of 4 (1.00 mmol) in dry dichloromethane 
(4.0 ml), SOCl2 (4.00 mmol, 0.3 mL) was slowly added, followed by two drops of 
dimethylformamide. The resulting mixture was then stirred for 2 h at room temperature. Afterwards, 
the solvent was evaporated under reduced pressure, and the excess of SOCl2 was removed by 
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azeotropic distillation with toluene. 2-Amino-1,3,4-thiadiazole, 2 (1.00 mmol, 0.227 g) and dry 
dioxane were added to the formed acid chloride, without its previous isolation, and the mixture was 
then refluxed for 12 hours. After cooling, 20.0 ml of distilled water was slowly added to the solution 
with vigorous stirring at room temperature, followed with a formation of precipitate (5a-m). Stirring 
was continued for 1 hour and precipitate was then filtrated, washed with water and dried over CaCl2. 
All compounds (except 5e) contained a smaller quantity of dioxane which was not removed even after 
drying at 110 °C for 12 h. To remove dioxane, final compounds 5j and 5l were dissolved in N,N-
dimethylformamide and 5k was dissolved in dimethyl sulfoxide, after which distilled water was 
added, followed with a formation of precipitate. The formed precipitate was then filtrated, washed 
with water and dried over CaCl2. All other final compounds (5a-d, 5f-i and 5m) were dissolved in 
tetrahydrofuran and solvent was evaporated to dryness under reduced pressure. 
 
4.1.2.1. (E)-4-(3-Oxo-3-phenylprop-1-en-1-yl)benzoic acid (4a): 1H NMR (200 MHz, DMSO-d6): 
7.55-7.69, (m, 3H, Ar-H); 7.78, (d, 1H, JAB = 15.8 Hz, CH=); 8.00, (s, 4H, Ar-H); 8.06, (d, 1H, JBA = 
15.8 Hz, CH=); 8.18, (d, 2H, J = 7.4 Hz, Ar-H); 13.16, (bs, 1H, OH); 13C NMR (50 MHz, DMSO-d6): 
124.44, 128.71 (2C), 128.95 (4C), 129.83 (2C), 132.26, 133.40, 137.51, 138.88, 142.63, 166.93, 
189.32. 
 
4.1.2.2. (Z)-4-(3-Oxo-3-(o-tolyl)prop-1-en-1-yl)benzoic acid (4b): 1H NMR (200 MHz, DMSO-d6): 
2.39, (s, 3H, CH3); 7.31-7.38, (m, 2H, Ar-H); 7.44, (d, 1H, JAB = 7.0 Hz, CH=); 7.53, (s, 1H, Ar-H); 
7.68, (d, 1H, JBA = 7.0 Hz, CH=); 7.90, (d, 2H, JAB = 8.2 Hz, Ar-H); 7.97, (d, 2H, JBA = 8.2 Hz, Ar-
H); 13.13, (bs, 1H, OH); 13C NMR (50 MHz, DMSO-d6): 20.13, 125.88, 128.35, 128.60, 128.85 (2C), 
129.84 (2C), 131.03, 131.41, 132.32, 136.76, 138.55, 138.62, 143.24, 166.89, 194.77. 
 
4.1.2.3. (E)-4-(3-Oxo-3-(m-tolyl)prop-1-en-1-yl)benzoic acid (4c): 1H NMR (200 MHz, DMSO-d6): 
2.42, (s, 3H, CH3); 7.42-7.51, (m, 2H, Ar-H); 7.77, (d, 1H, JAB = 15.6 Hz, CH=); 7.96-8.04, (m, 6H, 
Ar-H); 8.05, (d, 1H, JBA = 7.0 Hz, CH=); 13.81, (bs, 1H, OH); 
13C NMR (50 MHz, DMSO-d6): 20.99, 
124.50, 125.92, 128.79, 128.95 (2C), 129.11, 129.81 (2C), 132.22, 134.01, 137.55, 138.37, 138.91, 
142.45, 166.93, 189.30. 
 
4.1.2.4. (E)-4-(3-Oxo-3-(p-tolyl)prop-1-en-1-yl)benzoic acid (4d): 1H NMR (200 MHz, DMSO-d6): 
2.40, (s, 3H, CH3); 7.38, (d, 2H, JAB = 7.8 Hz, Ar-H); 7.78, (d, 1H, JAB = 15.6 Hz, CH=); 7.99, (s, 4H, 
Ar-H); 8.03, (d, 1H, JBA = 15.6 Hz, CH=); 8.09, (d, 2H, JBA = 7.8 Hz, Ar-H); 13.09, (bs, 1H, OH); 
13C 
NMR (50 MHz, DMSO-d6): 21.36, 124.42, 128.92 (2C), 128.98 (2C), 129.55 (2C), 129.88 (2C), 
132.21, 135.04, 139.00, 142.32, 143.96, 167.02, 188.70. 
 
4.1.2.5. (Z)-4-(3-(2-Methoxyphenyl)-3-oxoprop-1-en-1-yl)benzoic acid (4e): 1H NMR (200 MHz, 
DMSO-d6): 3.88, (s, 3H, OCH3); 7.07, (t, 1H, J = 7.2 Hz, Ar-H);  7.20, (d, 1H, JAB = 8.2 Hz, CH=); 
7.46-7.63, (m, 3H, Ar-H); 7.53, (d, 1H, JBA = 8.2 Hz, CH=); 7.85, (d, 2H, JAB = 8.2 Hz, Ar-H); 7.97, 
(d, 2H, JBA = 8.2 Hz, Ar-H); 13.09, (bs, 1H, OH); 
13C NMR (50 MHz, DMSO-d6): 56.07, 112.60, 
120.79, 128.70 (3C), 129.14, 129.85, 130.00 (2C), 132.18, 133.52, 138.94, 141.05, 158.11, 167.00, 
192.05. 
 
4.1.2.6. (E)-4-(3-(3-Methoxyphenyl)-3-oxoprop-1-en-1-yl)benzoic acid (4f): 1H NMR (200 MHz, 
DMSO-d6): 3.85, (s, 3H, OCH3); 7.25, (dd, 1H, J = 8.0 and 2.2 Hz, Ar-H);  7.50, (t, 1H, J = 8.0 Hz, 
Ar-H); 7.63, (s, 1H, Ar-H); 7.77, (d, 1H, JAB = 15.6 Hz, CH=); 7.79, (d, 1H, J = 8.0 Hz, Ar-H); 7.98, 
(d, 2H, JAB = 8.6 Hz, Ar-H); 8.02, (d, 2H, JBA = 8.6 Hz, Ar-H); 8.04, (d, 1H, JBA = 15.6 Hz, CH=); 
13.09, (bs, 1H, OH); 13C NMR (50 MHz, DMSO-d6): 55.56, 113.29, 119.53, 121.33, 124.43, 129.09 
(2C), 129.89 (2C), 130.12, 132.31, 138.92, 138.97, 142.78, 159.78, 167.03, 189.04. 
 
4.1.2.7. (E)-4-(3-(4-Methoxyphenyl)-3-oxoprop-1-en-1-yl)benzoic acid (4g): 1H NMR (200 MHz, 
DMSO-d6): 3.87, (s, 3H, OCH3); 7.09, (d, 2H, J = 9.0 Hz, Ar-H); 7.74, (d, 1H, JAB = 15.6 Hz, CH=); 
7.99, (s, 4H, Ar-H);  8.06, (d, 1H, JBA = 15.6 Hz, CH=); 8.19, (d, 2H, JBA = 9.0 Hz, Ar-H); 13.11, (bs, 
1H, OH); 13C NMR (50 MHz, DMSO-d6): 55.75, 114.25 (2C), 124.43, 128.93 (2C), 129.87 (2C), 
130.45, 131.21 (2C), 132.10, 139.12, 141.85, 163.56, 167.03, 187.46. 
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4.1.2.8. (Z)-4-(3-(2-Fluorophenyl)-3-oxoprop-1-en-1-yl)benzoic acid (4h): 1H NMR (200 MHz, 
DMSO-d6): 7.36, (d, 1H, JAB = 7.6 Hz, CH=); 7.38-7.44, (m, 1H, Ar-H); 7.52-7.74, (m, 2H, Ar-H); 
7.68, (d, 1H, JBA = 7.6 Hz, CH=); 7.81, (t, 1H, J = 7.6 Hz, Ar-H); 7.91, (d, 2H, JAB = 8.2 Hz, Ar-H);  
7.99, (d, 2H, JBA = 8.2 Hz, Ar-H); 13.07, (bs, 1H, OH); 
13C NMR (50 MHz, DMSO-d6): 116.85 (JCF = 
22.2 Hz), 125.05 (JCF = 3.3 Hz), 126.79 (JCF = 12.9 Hz), 127.70 (JCF = 3.7 Hz), 128.99 (2C), 129.98 
(2C), 130.74, 132.53, 134.67 (JCF = 8.8 Hz), 138.50, 143.20, 160.50 (JCF = 250.6 Hz), 166.94, 188.91. 
 
4.1.2.9. (E)-4-(3-(4-Fluorophenyl)-3-oxoprop-1-en-1-yl)benzoic acid (4i): 1H NMR (200 MHz, 
DMSO-d6): 7.42, (t, 2H, J = 8.8 Hz, Ar-H); 7.78, (d, 1H, JAB = 15.6 Hz, CH=); 7.96-8.01, (m, 4H, Ar-
H); 8.08, (d, 1H, JBA = 15.6 Hz, CH=); 8.28, (m, 2H, Ar-H); 13.15, (bs, 1H, OH); 
13C NMR (50 MHz, 
DMSO-d6): 115.99 (2C, JCF = 21.8 Hz), 124.16, 129.08 (2C), 129.87 (2C), 131.80 (2C, JCF = 9.3 Hz), 
132.33, 134.21 (JCF = 2.4 Hz), 138.88, 142.83, 165.33 (JCF = 250.8 Hz), 167.00, 187.80. 
 
4.1.2.10. (E)-4-(3-(4-Bromophenyl)-3-oxoprop-1-en-1-yl)benzoic acid (4j): 1H NMR (200 MHz, 
DMSO-d6): 7.79, (d, 1H, JAB = 15.6 Hz, CH=); 7.80, (d, 2H, JAB = 8.4 Hz, Ar-H); 7.96-8.05, (m, 4H, 
Ar-H); 8.05, (d, 1H, JBA = 15.6 Hz, CH=); 8.12, (d, 2H, JBA = 8.4 Hz, Ar-H); 13.17, (bs, 1H, OH); 
13C 
NMR (50 MHz, DMSO-d6): 124.01, 127.67, 129.10 (2C), 129.84 (2C), 130.77 (2C), 132.02 (2C), 
132.45, 136.47, 138.77, 143.15, 166.97, 188.40. 
 
4.1.2.11. (E)-4-(3-(4-Nitrophenyl)-3-oxoprop-1-en-1-yl)benzoic acid (4k): 1H NMR (200 MHz, 
DMSO-d6): 7.82, (d, 1H, JAB = 15.6 Hz, CH=); 8.00, (s, 4H, Ar-H); 8.06, (d, 1H, JBA = 15.6 Hz, 
CH=); 8.37, (s, 4H, Ar-H); 13.18, (bs, 1H, OH); 13C NMR (50 MHz, DMSO-d6): 123.97 (3C), 129.22 
(2C), 129.85 (2C), 130.09 (2C), 132.64, 138.54, 142.17, 144.09, 150.04, 166.93, 188.39. 
 
4.1.2.12. 4-(3-(Anthracen-1-yl)-3-oxoprop-1-en-1-yl)benzoic acid (4l): 1H NMR (200 MHz, DMSO-
d6): 7.54-7.68, (m, 3H, Ar-Hanthracene); 7.74, (d, 1H, JAB = 16.0 Hz, CH=); 7.86, (d, 1H, JBA = 16.0 Hz, 
CH=); 7.96, (d, 2H, JAB = 8.4 Hz, Ar-H); 8.00, (d, 2H, JBA = 8.4 Hz, Ar-H); 8.10-8.18, (m, 3H, Ar-
Hanthracene); 8.35, (d, 1H, J = 8.6 Hz, Ar-Hanthracene); 8.71, (s, 1H, Ar-Hanthracene); 9.13, (s, 1H, Ar-
Hanthracene); 13.17, (s, 1H, OH); 
13C NMR (50 MHz, DMSO-d6): 124.32, 124.76, 126.43 (2C), 127.25, 
127.76, 128.03, 128.54, 128.79, 128.98 (2C), 129.30, 129.92 (2C), 131.31, 131.61, 132.22, 132.35, 
133.10, 135.62, 138.80, 143.30, 166.99, 193.52. 
 
4.1.2.13. (E)-4-(3-Oxo-3-(thiophen-2-yl)prop-1-en-1-yl)benzoic acid (4m): 1H NMR (200 MHz, 
DMSO-d6): 7.33, (t, 1H, J = 4.4 Hz, Ar-Hthiophene); 7.76, (d, 1H, JAB = 15.6 Hz, CH=); 8.00, (s, 4H, Ar-
H); 8.01, (d, 1H, JBA = 15.6 Hz, CH=); 8.09, (d, 1H, J = 4.4 Hz, Ar-Hthiophene); 8.38, (d, 1H, J = 4.4 Hz, 
Ar-Hthiophene); 13.15, (s, 1H, OH); 
13C NMR (50 MHz, DMSO-d6): 124.24, 129.06 (3C), 129.88 (2C), 
132.31, 134.20, 136.02, 138.77, 141.87, 145.44, 166.99, 181.66. 
 
4.1.2.14. (E)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-oxo-3-phenylprop-1-en-1-
yl)benz-amide × H2O (5a): Beige powder; yield: 0.31 g (68%); mp: > 250ºC; 
1H NMR (200 MHz, 
DMSO-d6): 6.87, (d, 1H, J = 8.2 Hz, H-5phenolic); 7.24, (dd, 1H, J = 8.2 and 1.6 Hz, H-6phenolic); 7.39, 
(d, 1H, J = 1.6 Hz, H-2phenolic); 7.55-7.73, (m, 3H, Ar-H); 7.80, (d, 1H, JAB = 15.6 Hz, CH=); 8.09, (d, 
2H, J = 7.4 Hz, Ar-H); 8.12, (d, 1H, JBA = 15.6 Hz, CH=); 8.18-8.22, (m, 4H, Ar-H); 9.45, (s, 1H, 
OH); 9.61, (s, 1H, OH); 13.13, (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): 113.86, 116.34, 119.21, 
121.58, 124.57, 128.74 (2C), 128.93 (2C), 129.00 (4C), 133.05, 133.41, 137.50, 138.94, 142.48, 
146.00, 148.33, 158.58, 162.53, 164.76, 189.26; IR (KBr, cm-1): 3435; 2925; 1666; 1655; 1601; 1533; 
1309; 1296; 1219, 747; Anal. Calcd. For C24H17N3O4S×H2O (461.50 g/mol): C, 62.46; H, 4.15; N, 
9.10; S, 6.95; Found: C, 62.54; H, 4.14; N, 9.07; S, 6.97. 
 
4.1.2.15. (Z)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-oxo-3-(o-tolyl)prop-1-en-1-
yl)benz-amide × 1.5 H2O (5b): Light yellow powder; yield: 0.41 g (85%); mp: > 250ºC; 
1H NMR 
(200 MHz, DMSO-d6): 2.41, (s, 3H, CH3); 6.86, (d, 1H, J = 8.0 Hz, H-5phenolic); 7.24, (d, 1H, J = 8.0 
Hz, H-6phenolic); 7.33-7.38, (m, 2H, Ar-H and 1H,  H-2phenolic); 7.45, (d, 1H, JAB = 7.0 Hz, CH=); 7.58, 
(s, 2H, Ar-H); 7.72, (d, 1H, JBA = 7.0 Hz, CH=); 7.98, (d, 2H, JAB = 8.0 Hz, Ar-H); 8.17, (d, 2H, JBA = 
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8.0 Hz, Ar-H); 9.45, (s, 1H, OH); 9.61, (s, 1H, OH); 13.11, (s, 1H, NH); 13C NMR (50 MHz, DMSO-
d6): 20.18, 113.87, 116.34, 119.21, 121.58, 125.87, 128.47, 128.68, 128.88 (2C), 129.04 (2C), 131.06, 
131.43, 133.14, 136.83, 138.52, 138.69, 143.04, 146.00, 148.33, 158.60, 162.54, 164.81, 194.68; IR 
(KBr, cm-1): 3466; 3173; 1667; 1630; 1606; 1532; 1450; 1301; 1275; 807; Anal. Calcd. For 
C25H19N3O4S×1.5H2O (484.53 g/mol): C, 61.97; H, 4.58; N, 8.67; S, 6.62; Found: C, 61.99; H, 4.59; 
N, 8.65; S, 6.63. 
 
4.1.2.16. (E)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-oxo-3-(m-tolyl)prop-1-en-1-
yl)benz-amide (5c): Yellow powder; yield: 0.38 g (82%); mp: > 250ºC; 1H NMR (200 MHz, DMSO-
d6): 2.44, (s, 3H, CH3); 6.88, (d, 1H, J = 8.0 Hz, H-5phenolic); 7.26, (dd, 1H, J = 8.0 and 2.0 Hz, H-
6phenolic); 7.40, (d, 1H, J = 2.0 Hz, H-2phenolic); 7.44-7.53, (m, 2H, Ar-H);  7.81, (d, 1H, JAB = 15.6 Hz, 
CH=); 7.96-8.24, (m, 6H, Ar-H); 8.12, (d, 1H, JBA = 15.6 Hz, CH=), 9.46, (s, 1H, OH); 9.62, (s, 1H, 
OH); 13.14, (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): 20.98, 113.84, 116.31, 119.17, 121.54, 
124.67, 125.94, 128.79, 128.97 (4C), 129.12, 133.01, 134.03, 137.52, 138.37, 138.97, 142.29, 145.97, 
148.30, 158.52, 162.50, 164.74, 189.26; IR (KBr, cm-1): 3426; 3169; 1644; 1653; 1607; 1532; 1309; 
1297; 1254; 758; Anal. Calcd. For C25H19N3O4S (457.51 g/mol): C, 65.63; H, 4.19; N, 9.18; S, 7.01; 
Found: C, 65.61; H, 4.18; N, 9.20; S, 7.02. 
 
4.1.2.17. (E)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-oxo-3-(p-tolyl)prop-1-en-1-
yl)benz-amide (5d): Yellow powder; yield: 0.38 g (84%); mp: > 250ºC; 1H NMR (200 MHz, DMSO-
d6): 2.71, (s, 3H, CH3); 6.87, (d, 1H, J = 8.2 Hz, H-5phenolic); 7.24, (dd, 1H, J = 8.2 and 1.8 Hz, H-
6phenolic); 7.39, (d, 1H, J = 1.8 Hz, H-2phenolic); 7.39, (d, 2H, JAB = 7.8 Hz, Ar-H); 7.78, (d, 1H, JAB = 
15.6 Hz, CH=); 8.06-8.13, (m, 4H, Ar-H); 8.11, (d, 1H, JBA = 15.6 Hz, CH=); 8.20, (d, 2H, JBA = 7.8 
Hz, Ar-H); 9.46, (s, 1H, OH); 9.61, (s, 1H, OH); 13.13, (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): 
21.31, 113.88, 116.34, 119.20, 121.59, 124.61, 128.96 (6C), 129.49 (2C), 132.97, 135.01, 139.02, 
142.09, 143.92, 146.00, 148.33, 158.59, 162.53, 164.78, 188.67; IR (KBr, cm-1): 3434; 3192; 2920; 
1668; 1654; 1609; 1533; 1308; 1296; 1210; 759; Anal. Calcd. For C25H19N3O4S (457.51 g/mol): C, 
65.63; H, 4.19; N, 9.18; S, 7.01; Found: C, 65.60; H, 4.20; N, 9.17; S, 7.00. 
 
4.1.2.18. (Z)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-(2-methoxyphenyl)-3-oxoprop-1-
en-1-yl)benzamide × 2 H2O (5e): Yellow-green powder; yield: 0.36 g (70%); mp: > 250ºC; 
1H NMR 
(200 MHz, DMSO-d6): 3.89, (s, 3H, OCH3); 6.86, (d, 1H, J = 8.2 Hz, H-5phenolic); 7.08, (t, 1H, J = 7.4 
Hz, Ar-H); 7.22, (d, 1H, JAB = 8.2 Hz, CH=); 7.23, (d, 1H, J = 8.2 Hz, H-6phenolic); 7.38, (s, 1H, H-
2phenolic); 7.54, (d, 1H, JBA = 8.2 Hz, CH=); 7.58, (s, 3H, Ar-H); 7.93, (d, 2H, JAB = 8.2 Hz, Ar-H); 
8.17, (d, 2H, JBA = 8.2 Hz, Ar-H); 9.45, (s, 1H, OH); 9.61, (s, 1H, OH); 13.11, (s, 1H, NH); 
13C NMR 
(50 MHz, DMSO-d6): 56.03, 112.56, 113.87, 116.34, 119.22, 120.72, 121.60, 128.62 (2C), 128.73, 
129.10 (2C), 129.28, 129.76, 132.99, 133.41, 138.95, 140.84, 146.00, 148.33, 158.06, 158.59, 162.51, 
164.81, 192.00; IR (KBr, cm-1): 3434; 3236; 2934; 1661; 1607; 1536; 1448; 1315; 1295; 1245; 747; 
Anal. Calcd. For C25H19N3O5S×2H2O (509.54 g/mol): C, 58.93; H, 4.55; N, 8.25; S, 6.29; Found: C, 
58.95; H, 4.57; N, 8.26; S, 6.27. 
 
4.1.2.19. (E)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-(3-methoxyphenyl)-3-oxoprop-
1-en-1-yl)benzamide × H2O (5f): Dark yellow powder; yield: 0.38 g (78%); mp: > 250ºC; 
1H NMR 
(200 MHz, DMSO-d6): 3.86, (s, 3H, OCH3); 6.87, (d, 1H, J = 8.0 Hz, H-5phenolic); 7.23-7.27, (m, 1H, 
Ar-H and 1H, H-6phenolic); 7.39, (s, 1H, H-2phenolic); 7.51, (t, 1H, J = 8.0 Hz, Ar-H); 7.65, (s, 1H, Ar-H); 
7.80, (d, 1H, JAB = 15.6 Hz, CH=); 7.82, (d, 1H, J = 8.0 Hz, Ar-H); 8.09, (d, 2H, JAB = 8.6 Hz, Ar-H); 
8.10, (d, 1H, JBA = 15.6 Hz, CH=); 8.20, (d, 2H, JBA = 8.6 Hz, Ar-H); 9.45, (s, 1H, OH); 9.61, (s, 1H, 
OH); 13.13, (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): 55.54, 113.32, 113.88, 116.35, 119.23, 
119.46, 121.30, 121.61, 124.59, 129.04 (4C), 130.06, 133.06, 138.94 (2C), 142.56, 146.01, 148.34, 
158.63, 159.74, 162.55, 164.78, 189.00; IR (KBr, cm-1): 3434; 2937; 1663; 1607; 1538; 1448; 1317; 
1293; 1259; 759; Anal. Calcd. For C25H19N3O5S×H2O (491.52 g/mol): C, 61.09; H, 4.31; N, 8.55; S, 
6.52; Found: C, 61.11; H, 4.29; N, 8.57; S, 6.53. 
 
4.1.2.20. (E)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-(4-methoxyphenyl)-3-oxoprop-
1-en-1-yl)benzamide × 0.5 H2O (5g): Light yellow powder; yield: 0.34 g (70%); mp: > 250ºC; 
1H 
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NMR (200 MHz, DMSO-d6): 3.88, (s, 3H, OCH3); 6.87, (d, 1H, J = 8.2 Hz, H-5phenolic); 7.10, (d, 2H, 
JAB = 9.0 Hz Ar-H); 7.24, (dd, 1H, J = 8.2 and 2.0 Hz, H-6phenolic); 7.39, (d, 1H, J = 2.0 Hz, H-2phenolic); 
7.76, (d, 1H, JAB = 15.6 Hz, CH=); 8.08, (d, 2H, JAB = 8.4 Hz, Ar-H); 8.13, (d, 1H, JBA = 15.6 Hz, 
CH=); 8.20, (d, 2H, JBA = 8.4 Hz, Ar-H); 8.21, (d, 2H, JBA = 9.0 Hz, Ar-H); 9.46, (s, 1H, OH); 9.61, 
(s, 1H, OH); 13.12, (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): 55.71, 113.84, 114.20 (2C), 116.32, 
119.18, 121.56, 124.62, 128.46, 128.89 (2C), 128.98 (2C), 130.42, 131.17 (2C), 139.14, 141.61, 
145.98, 148.31, 158.48, 162.52, 163.53, 164.78, 187.40; IR (KBr, cm-1): 3406; 3173; 2940; 1670; 
1654; 1605; 1593; 1533; 1307; 1263; 1172; 765; Anal. Calcd. For C25H19N3O5S×0.5H2O (482.52 
g/mol): C, 62.23; H, 4.18; N, 8.71; S, 6.64; Found: C, 62.25; H, 4.19; N, 8.72; S, 6.65. 
 
4.1.2.21. (Z)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-(2-fluorophenyl)-3-oxoprop-1-
en-1-yl)benzamide × H2O (5h): Yellow powder; yield: 0.26 g (54%); mp: > 250ºC; 
1H NMR (200 
MHz, DMSO-d6): 6.86, (d, 1H, J = 8.2 Hz, H-5phenolic); 7.24, (dd, 1H, J = 8.2 and 1.6 Hz, H-6phenolic); 
7.37, (d, 1H, JAB = 7.6 Hz, CH=); 7.39-7.44, (m, 1H, Ar-H and 1H, H-2phenolic); 7.58-7.80 (m, 2H, Ar-
H and 1H, CH=), 7.83 (t, 1H, J = 7.6 Hz, Ar-H); 7.99, (d, 2H, JAB = 8.2 Hz, Ar-H); 8.18, (d, 1H, JBA = 
8.2 Hz, Αr-Η); 9.46, (s, 1H, OH); 9.61, (s, 1H, OH); 13.14, (s, 1H, NH); 13C NMR (50 MHz, DMSO-
d6): 113.86, 116.33, 116.78 (JCF = 22.2 Hz), 119.21, 121.57, 124.97 (JCF = 3.3 Hz), 126.76 (JCF = 12.8 
Hz), 127.81 (JCF = 3.7 Hz), 128.92 (2C), 129.10 (2C), 130.70 (JCF = 2.1 Hz), 133.34, 134.59 (JCF = 8.8 
Hz), 138.51, 142.97, 146.00, 148.33, 158.64, 160.46 (JCF = 250.8 Hz), 162.51, 164.79, 188.84; IR 
(KBr, cm-1): 3405; 2928; 1671; 1662; 1611; 1539; 1451; 1317; 1293; 1268; 755; Anal. Calcd. For 
C24H16N3O4SF×H2O (479.49 g/mol): C, 60.11; H, 3.96; N, 8.76; S, 6.69; Found: C, 60.13; H, 3.95; N, 
8.78; S, 6.70. 
 
4.1.2.22. (E)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-(4-fluorophenyl)-3-oxoprop-1-
en-1-yl)benzamide × 2 H2O (5i): Yellow powder; yield: 0.31 g (63%); mp: > 250ºC; 
1H NMR (200 
MHz, DMSO-d6): 6.87, (d, 1H, J = 8.2 Hz, H-5phenolic); 7.24, (dd, 1H, J = 8.2 and 1.6 Hz, H-6phenolic); 
7.38, (d, 1H, J = 1.6 Hz, H-2phenolic); 7.42, (t, 2H, J = 8.8 Hz, Ar-H); 7.81, (d, 1H, JAB = 15.6 Hz, 
CH=); 8.09, (d, 2H, JAB = 8.4 Hz, Ar-H); 8.14, (d, 1H, JBA =15.6 Hz, CH=); 8.20, (d, 2H, JBA = 8.4 
Hz, Ar-H); 8.31, (m, 2H, Ar-H); 9.45, (s, 1H, OH); 9.61, (s, 1H, OH); 13.13, (s, 1H, NH); 13C NMR 
(50 MHz, DMSO-d6): 113.84, 115.93 (2C, JCF = 21.6 Hz), 116.31, 119.18, 121.55, 124.32, 128.99 
(2C), 129.02 (2C), 131.76 (2C, JCF = 9.4 Hz), 133.06, 134.17 (JCF = 2.6 Hz), 138.88, 142.61, 145.98, 
148.31, 158.50 (JCF = 6.7 Hz), 162.51, 164.73, 165.28 (JCF = 250.8 Hz), 187.75; IR (KBr, cm
-1): 3225; 
3071; 2951; 1668; 1654; 1603; 1538; 1508; 1308; 1220; 831; Anal. Calcd. For C24H16N3O4SF×2H2O 
(497.50 g/mol): C, 57.94; H, 4.05; N, 8.45; S, 6.44; Found: C, 57.92; H, 4.06; N, 8.43; S, 6.45. 
 
4.1.2.23. (E)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-(4-bromophenyl)-3-oxoprop-1-
en-1-yl)benzamide × 2 H2O (5j): Yellow-green powder; yield: 0.49 g (87%); mp: > 250ºC; 
1H NMR 
(200 MHz, DMSO-d6): 6.87, (d, 1H, J = 7.6 Hz, H-5phenolic); 7.24, (d, 1H, J = 7.6 Hz, H-6phenolic); 7.39, 
(s, 1H, H-2phenolic); 7.79, (d, 2H, J = 8.4 Hz, Ar-H); 7.80, (d, 1H, JAB = 15.6 Hz, CH=); 8.05-8.21, (m, 
6H, Ar-H and 1H, CH=); 9.46, (s, 1H, OH); 9.61, (s, 1H, OH); 13.13, (s, 1H, NH); 13C NMR (50 
MHz, DMSO-d6): 113.85, 116.32, 119.19, 121.55, 124.20, 127.63, 129.00 (2C), 129.08 (2C), 130.75 
(2C), 131.99 (2C), 133.14, 136.46, 138.83, 142.95, 145.99, 148.32, 158.59, 162.53, 164.69, 188.37; 
IR (KBr, cm-1): 3406; 3033; 2923; 1662; 1655; 1600; 1584; 1534; 1305; 1214; 759; Anal. Calcd. For 
C24H16N3O4SBr×2H2O (558.41 g/mol): C, 51.62; H, 3.61; N, 7.52; S, 5.74; Found: C, 51.64; H, 3.60; 
N, 7.54; S, 5.75. 
 
4.1.2.24. (E)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-(4-nitrophenyl)-3-oxoprop-1-en-
1-yl)benzamide x 4 H2O  (5k): Brown powder; yield: 0.30 g (53%); mp: > 250ºC; 
1H NMR (200 MHz, 
DMSO-d6): 6.86, (d, 1H, J = 6.4 Hz, H-5phenolic); 7.24, (d, 1H, J = 6.4 Hz, H-6phenolic); 7.38, (s, 1H, H-
2phenolic); 7.86, (d, 1H, JAB = 15.6 Hz, CH=); 8.09-8.19, (m, 4H, Ar-H and 1H, CH=); 8.40, (s, 4H, Ar-
H); 9.45, (s, 1H, OH); 9.61, (s, 1H, OH); 13.16, (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): 113.84, 
116.31, 119.18, 121.54, 123.95 (2C), 124.22, 129.02 (2C), 129.23 (2C), 130.09 (2C), 133.36, 138.61, 
142.18, 143.91, 145.98, 148.33, 150.07, 158.59, 162.51, 164.71, 188.42; IR (KBr, cm-1): 3404; 3165; 
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2930; 1664; 1655; 1607; 1590; 1523; 1306; 1298; 1212; 747; Anal. Calcd. For C24H16N4O6S×4H2O 
(560.54 g/mol): C, 51.43; H, 4.32; N, 10.00; S, 5.72; Found: C, 51.45; H, 4.31; N, 9.98; S, 5.73. 
 
4.1.2.25. (E)-4-(3-(Anthracen-1-yl)-3-oxoprop-1-en-1-yl)-N-(5-(3,4-dihydroxyphenyl)-1,3,4-
thiadiazol-2-yl)benzamide × H2O (5l): Dark orange powder; yield: 0.43 g (76%); mp: > 250ºC; 
1H 
NMR (200 MHz, DMSO-d6): 6.87, (d, 1H, J = 8.2 Hz, H-5phenolic); 7.25, (d, 1H, J = 8.2 Hz, H-6phenolic); 
7.39, (s, 1H, H-2phenolic); 7.55-7.70, (m, 3H, Ar-Hanthracene), 7.78, (d, 1H, JAB = 15.8 Hz, CH=); 7.92, (d, 
1H, JBA = 15.8 Hz, CH=); 7.98-8.22, (m, 4H, Ar-H and 3H, Ar-Hanthracene); 8.37, (d, 1H, J = 8.4 Hz, 
Ar-Hanthracene); 8.73, (s, 1H, Ar-Hanthracene); 9.16, (s, 1H, Ar-Hanthracene); 9.46, (s, 1H, OH); 9.62, (s, 1H, 
OH); 13.14, (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): 113.90, 116.36, 119.24, 121.62, 124.27, 
124.72, 126.38 (2C), 127.21, 127.72, 127.99, 128.65, 128.74 (2C), 128.93 (2C), 129.05, 131.28, 
131.58, 132.19, 133.10, 135.57, 138.82, 143.06, 146.02, 148.35, 158.63, 162.54, 164.80, 193.43; IR 
(KBr, cm-1): 3405; 3047; 2930; 1655; 1607; 1538; 1510; 1302; 1290; 1255; 1201; 749; Anal. Calcd. 
For C32H21N3O4S×H2O (561.62 g/mol): C, 68.43; H, 4.13; N, 7.48; S, 5.71; Found: C, 68.40; H, 4.14; 
N, 7.50; S, 5.73. 
 
4.1.2.26. (E)-N-(5-(3,4-Dihydroxyphenyl)-1,3,4-thiadiazol-2-yl)-4-(3-oxo-3-(thiophen-2-yl)prop-1-en-
1-yl)benzamide (5m): Yellow powder; yield: 0.28 g (62%); mp: > 250ºC; 1H NMR (200 MHz, 
DMSO-d6): 6.87, (d, 1H, J = 8.2 Hz, H-5phenolic); 7.24, (dd, 1H, J = 8.2 and 1.8 Hz, H-6phenolic); 7.34, (t, 
1H, J = 4.4 Hz, Ar-Hthiophene); 7.39, (d, 1H, J = 1.8 Hz, H-2phenolic); 7.79, (d, 1H, JAB = 15.6 Hz, CH=); 
8.06, (d, 1H, JBA = 15.6 Hz, CH=); 8.08, (d, 2H, JAB = 8.4 Hz, Ar-H); 8.10, (d, 1H, J = 4.4 Hz, Ar-
Hthiophene); 8.20, (d, 2H, JBA = 8.4 Hz, Ar-H); 8.41, (d, 1H, J = 4.4 Hz, Ar-Hthiophene); 9.47, (s, 1H, OH); 
9.62, (s, 1H, OH); 13.13, (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): 113.85, 116.33, 119.20, 
121.55, 124.44, 129.01 (5C), 133.07, 134.18, 135.99, 138.80, 141.66, 145.39, 145.99, 148.32, 158.55, 
162.53, 164.81, 181.63; IR (KBr, cm-1): 3406; 2927; 1671; 1654; 1595; 1540; 1413; 1317; 1292; 
1189; 760; Anal. Calcd. For C22H15N3O4S2 (449.51 g/mol): C, 58.78; H, 3.36; N, 9.35; S, 14.26; 
Found: C, 58.80; H, 3.34; N, 9.36; S, 14.21. 
 
 
4.2. Biology 
 
4.2.1. Cytotoxic activity 
 
The cytotoxic activity of the newly synthesized 1,3,4-thiadiazole-chalcone hybrids containing 
antioxidant phenolic moiety was evaluated on three human malignant cell lines: cervical 
adenocarcinoma HeLa, acute promyelocytic leukemia HL-60, lung carcinoma A549, and human 
normal lung fibroblasts MRC-5, as described in our previous studies.20 All tested cell lines were 
obtained from the American Type Culture Collection (Manassas, VA, USA). HeLa (2,000 cells per 
well), A549 (5,000 cells per well) and MRC-5 cells (5,000 cells per well) were seeded into 96-well 
microtiter plates and after 20 h the five different concentrations of the compounds (ranging from 6.25 
µM to 100 µM or 3.125 µM to 50 µM) were added to the cells. The control cell samples were 
incubated in nutrient medium only. HL-60 cells (7,000 cells per well), were seeded 2 h before the 
addition of solutions of the compounds. Stock solutions of the compounds were made in DMSO at a 
concentration of 5 mM. The cell survival was measured by MTT assay after treatment that lasted 72h, 
according to the standard procedure firstly described by Mosmann,52 and which was modified by 
Ohno and Abe,53 as described previously in more detail.20 The concentrations of compounds dissolved 
in DMSO and further diluted in nutrient medium were carefully chosen in order to eliminate any toxic 
side effect of DMSO on all tested human cell lines. The maximum final concentrations of DMSO did 
not exceed 1%. 
The chemotherapy drug cisplatin was used as a positive control. Each of the three independent 
experiment was performed in triplicate.  
 
4.2.2. DPPH free radical scavenging assay 
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The determination of the DPPH free radical scavenging activity of the studied compounds 
was conducted according to method described by Kontogiorgis et al.54 Briefly, 1 mL (0.05 mM) of 
DPPH solution in methanol was mixed with an equivalent volume of the tested compound (20 µL of 
compound solution in DMSO and 980 µL of methanol). The sample was stored in dark at room 
temperature. The absorbance was acquired at 517 nm after incubation period of 30 min. Methanol was 
taken as control. IC50 values represent the concentration necessary to obtain 50% of a maximum 
scavenging activity. Ascorbic acid was used as positive control. The results are presented as mean ± 
SD calculated from the independent triplicate experiments using Microsoft Excel software. 
 
 
 
 
4.2.3. Determination of intracellular ROS levels 
 
Human HeLa cells were incubated with subtoxic IC20 concentrations of the selected 
compounds 5a, 5c, 5f and 5m (applied concentration was 10 µM for each compound) for 24 h. 
Afterwards, the HeLa cells were collected, washed with phosphate buffered saline (PBS) and 
incubated in a solution of 30 µM 2′,7′-dichlorodihydrofluorescein diacetate (Sigma Aldrich) in PBS 
for 45 min at 37°C, according to standard experimental procedure which we described previously.55 
The cells were then washed with PBS. The part of treated cell samples was analysed immediately, 
while the other part of treated cells samples was exposed to 10 mM hydrogen peroxide solution 
(H2O2) for 30 min at 37°C. After 30 min, these cells were washed with PBS and collected. The 
intensity of green fluorescence emitted by the dichlorofluorescein was determined on a FACSCalibur 
flow cytometer (BD Biosciences Franklin Lakes, NJ, USA). The data (20,000 events acquired for 
each cell sample) were analysed using CELLQuest software (BD Biosciences).  
 
 
4.2.4. Cell cycle analysis by flow cytometry 
 
Human cervical carcinoma HeLa cells were incubated with compounds 5a, 5c, 5f and 5m for 
24 h (applied concentrations corresponded to IC50 and 2IC50 concentrations which were determined 
after 72 h treatment).  Following 24 h incubation, the cells were collected, washed with PBS and fixed 
in 70% ethanol, according to standard protocol.56 Cell samples were stored at -20°C for at least one 
week before staining. Afterwards, HeLa cells were collected by centrifugation, washed, resuspended 
in PBS containing RNase A and incubated for 30 min at 37°C. Subsequently the propidium iodide 
staining solution was added to the cells. Percentages of HeLa cells within specific phases of the cell 
cycle were assessed using a BD FACSCalibur flow cytometer. The analyses of acquired data (10,000 
events collected for each gated cell sample) were performed using a CELLQuest software. Cell cycle 
distribution data are presented as mean±S.D. of three independent experiments. The statistical 
significance of differences between the control and cell samples exposed to tested compounds was 
evaluated using one-way ANOVA with Dunnett’s post test. p values below 0.05 were considered 
statistically significant.  
 
 
4.2.5. Identification of target caspases 
 
To investigate whether the examined compounds could induce apoptosis in treated HeLa cells 
the percentages of subG1 cells in the samples pretreated with specific caspase inhibitors were 
detyermined, as previously described in our previous research.20 The HeLa cells were pretreated for 2 
h with 40 µM concentrations of the specific peptide caspase inhibitors: Z-DEVD-FMK, a caspase-3 
inhibitor, Z-IETD-FMK, a caspase-8 inhibitor and Z-LEHD-FMK, a caspase-9 inhibitor (R&D 
Systems, Minneapolis, USA).  
 
 
4.2.6. Gene and microRNA expression analyses 
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HeLa cells were seeded into 75 cm2 cell culture flasks (4×106 cells/flask). After 2 h, the cells 
were treated with low subtoxic IC20 concentrations of the compounds 5a, 5c, 5f and 5m for 24 h (10 
µM for each compound).  Control cells were grown in nutrient medium only. After 24h incubation, 
the cells were collected, washed and the cell samples were stored at -80°C until further analyses. Total 
RNA was extracted with TriReagent (Sigma), according to manufacturer’s protocol. Gene expression 
was quantified by two-step reverse transcription reaction followed by real-time quantitative PCR (RT-
qPCR) with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems by Thermo Fisher 
Scientific, Vilnius, Lithuania). Reaction of cDNA amplification was performed with MMP2 
(Hs01548727_m1), MMP9 (Hs00957562_m1), VEGFA (Hs00900055_m1), and TIMP3 
(Hs00165949_m1) assays, using TaqMan technology.  
Stem-loop reverse transcription and RT-qPCR were used for miR-21 (ID 000397), miR-133b (ID 
002247), miR-155 (ID 002623), and miR-206 (ID 000510) expression analysis. 
Gene and microRNA expression values were normalized to GAPDH (Hs02758991_g1), and small 
nuclear RNA-RNU6 B (ID001093) and calculated by comparative ∆∆Ct method, with 7500 System 
SDS software (Applied Biosystems, Foster City, California, USA). 
 
 
4.2.7. Endothelial cell tube formation assay 
 
To explore whether antiangiogenic effects of the compounds were explored on human 
umbilical vein endothelial EA.hy926 cells.57,58 The EA.hy926 cells seeded on Corning® Matrigel® 
basement membrane matrix (Corning: cat. number 356234) were exposed to suboxic IC20 
concentrations of the four tested compounds (the compounds 5a, 5c, 5f (6.5 µM for each compound) 
and 5m (8 µM) for 20 h. After treatment that lasted 20 h, the photomicrographs of EA.hy926 cells 
were captured under the inverted phase-contrast microscope. 
 
 
4.2.8. Interaction with DNA 
 
4.2.8.1. Absorption spectral measurements 
 
Calf thymus DNA (lyophilized, highly polymerized, obtained from Serva, Heidelberg) (CT-
DNA) was used for the experiments. The stock solution was prepared by dissolving the DNA in Tris 
buffer (10 mM Tris-HCl pH 7.9) overnight at 4 °C. This stock solution was stored at 4 °C and was 
stable for several days. A solution of CT-DNA in water gave a ratio of UV absorbance at 260 and 280 
nm, A260/A280 of 1.89–2.01, indicating that DNA was sufficiently free of protein. The concentration of 
DNA (3.16 mg mL−1) was determined from the UV absorbance at 260 nm using the extinction 
coefficient ε260=6600 M
−1 cm−1.59 1,3,4–thiadiazole-chalcone hybrids 5a, 5c, 5f and 5m were 
dissolved in dimethyl sulfoxide in concentration of 2 mM. These solutions were used as stock 
solutions. 
For an UV-Vis measurement, a small volume of a stock solution of the compound (20 µL) was added 
to DNA solution (10 µL of CT-DNA) and the volume was adjusted up to 1 mL with 40 mM 
bicarbonate buffer, pH 8.4. Reaction mixtures were incubated at 37 °C for 90 min with occasional 
vortexing. UV–Vis spectra were recorded on a UV-1800 Shimadzu UV/Visible spectrophotometer 
operating from 200 to 800 nm in 1.0 cm quartz cells. Spectra of the compounds of the same 
concentrations were also recorded, as well as spectra of CT-DNA.  
The percentage of hyperchromism or hypocromism was determined from  
{[(εDNA + εCOMP) – εB]/ (εDNA + εCOMP)} x 100 (1) 
 where εDNA is the extinction coefficient of CT-DNA, εCOMP is the extinction coefficient of free 
compound and εB is the extinction coefficient of the bound compound complex.  
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The absorbance titrations were performed at a fixed concentration of the compound and gradually 
increasing concentration of double stranded CT-DNA. The absorbance at 259 nm was monitored for 
each concentration of DNA. The binding constant Kb was determined using the equation (2):
60 
 
[DNA] × (εa – εf)
−1 = [DNA] × (εb – εf)
 −1 + Kb
−1 × (εb – εf)
 −1, (2) 
 
where εa, εf, εb are absorbance/[compound], extinction coefficient of the free compound and the 
extinction coefficient of the bound compound, respectively. A plot of [DNA]/(εa – εf) versus [DNA] 
gave a slope and an intercept equal to 1/(εa – εf) and (1/Kb)(1/(εb – εf)), respectively. The binding 
constant Kb is calculated from the ratio of the slope to the intercept. 
 
 
4.2.8.2. Fluorescence measurements 
 
The competitive interactions of 1,3,4-thiadiazole-chalcone hybrids 5a, 5c, 5f and 5m and the 
fluorescence probe Hoechst 33258 (H), with CT-DNA have been studied by measuring the change of 
fluorescence intensity of H−DNA solution after addition of the compound. Reaction mixtures 
containing 100 µM of CT-DNA (calculated per phosphate) in 1 mL of 40 mM bicarbonate solution 
(pH 8.4) were pretreated with 1.5 µL of 1% H probe solution (28 µM final concentration) (in separate 
experiments) for 20 min and the mixture was analyzed by fluorescence measurement. Then the 
increasing concentrations of the compounds were successively added and the changes in the 
fluorescence intensity were measured using a Thermo Scientific Lumina Fluorescence spectrometer 
(Finland) equipped with a 150 W Xenon lamp. The slits on the excitation and emission beams were 
fixed at 10 nm. All measurements were performed by excitation at 350 nm in the range of 390−550 
nm. The control was H−CT-DNA solution. Compounds 5a, 5c, 5f and 5m, did not have fluorescence 
under applied conditions. The obtained fluorescence quenching data were analyzed according to the 
Stern–Volmer equation (3):61 
 
I0/I = 1 + Kr       (3) 
where I0 and I represent the fluorescence intensities of H−CT-DNA in absence and presence of the 
compounds, respectively, K is quenching constant and r is ratio of the bound concentration of a probe 
to the bound concentration of DNA (r = [compound]/[CT-DNA]. The K value is calculated from the 
ratio of the slope to the intercept from the plot of I0/I versus r. 
Primary spectra of all spectrometric measurements were imported into OriginPro 9.0 and were 
processed by this software package. 
 
4.2.8.3. Experiments with plasmid DNA 
 
Plasmid pUC19 (2686 bp in length, purchased from Sigma-Aldrich, USA) was prepared by its 
transformation in chemically competent cells Escherichia coli (E. coli) strain XL1 blue. Amplification 
of the clone was done according to the protocol for growing E. coli culture overnight in LB medium at 
37 °C62 and purification was performed using Qiagen Plasmid plus Maxi kit. Finally, DNA was eluted 
in 10 mM Tris-HCl buffer and stored at −20 °C. The concentration of plasmid DNA (0.460 µg/µL) 
was determined by measuring the absorbance of the DNA-containing solution at 260 nm. One optical 
unit corresponds to 50 µg mL−1 of double stranded DNA.  
Plasmid DNA (1 µL, 460 ng/ µL) was incubated with increasing volumes of 2 mM stock 
solution in DMSO of the compound (0.5, 1, 1.5, 2, 2.5, 3 and 4 µL) in a 20 µL reaction mixture in 40 
mM bicarbonate buffer (pH 8.4) at 37 °C, for 90 minutes. DMSO had no efects on DNA conformation 
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under aplied concentration. The reaction mixtures were vortexed from time to time. The reaction was 
terminated by short centrifugation at 10000 rpm and addition of 5 µL of loading buffer (0.25% 
bromophenol blue, 0.25% xylene cyanol FF and 30% glycerol in TAE buffer, pH 8.24 (40 mM Tris-
acetate, 1 mM EDTA)), and analyzed by an agarose electrophoresis. 
Interactions of the tested compounds with pUC19 in presence of Fe(II) and Fe(III) were done 
as follows. Solutions of 20 µL volume consisted of 1 µL or 2 µL FeSO4 (8 mM, freshly prepared in a 
sterile water) or 1 µL or 2 µL FeCl3 (8 mM, freshly prepared in a sterile water) with 4 µL of 2 mM 
solution of 1,3,4-thiadiazole-chalcone hybrids 5a, 5c, 5f and 5m in bicarbonate buffer were incubated 
at 37oC, for 60 minutes, then 1 µL of pUC19 were added to reaction mixtures and incubated further 
for 90 minutes. The reaction mixtures were vortexed from time to time and terminated by short 
centrifugation at 10000 rpm and addition of 5 µL of loading buffer and analyzed by agarose 
electrophoresis.  
 
4.2.8.4. Agarose electrophoresis 
 
The samples were subjected to electrophoresis on 1% agarose gel (Amersham Pharmacia-
Biotech, Inc) prepared in TAE buffer pH 8.24. The electrophoresis was performed at a constant 
voltage (80 V) until bromophenol blue had passed through 75% of the gel. A Submarine Mini-gel 
Electrophoresis Unit (Hoeffer HE 33) with an EPS 300 power supply was used. After electrophoresis, 
the gel was stained for 30 min by soaking it in an aqueous ethidium bromide solution (0.5 µg mL−1). 
The stained gel was illuminated under a UV transilluminator Vilber-Lourmat (France) at 312 nm and 
photographed with a Nikon Coolpix P340 Digital Camera through filter DEEP YELLOW 15 
(TIFFEN, USA). 
 
4.2.8.5. Comet assay 
 
Human normal MRC-5 cells were treated with four concentrations of selected compounds 5a, 
5c, 5f and 5m (applied concentrations were 25 µM, 12.5 µM, 6.25 µM and 3.125 µM for each 
compound) for 24 h. The IC20 subtoxic concentration was 25 µM for all four compounds, as 
determined by MTT test after 24 h treatment. After incubation, the cells were collected, washed with 
phosphate buffered saline (PBS), suspended in freezing medium (RPMI with 10% DMSO and 20 % 
FCS) and the cell samples were frozen at -80°C. 
The medium-throughput version of the single-cell gel electrophoresis assay was used to evaluate 
DNA damage as previously described63 with some modifications. Frozen MRC-5 cells were thawed 
by addition of 1 ml of PBS to a frozen 0.5 mL aliquot and as soon as the sample was thawed the 
suspended cells were centrifuged for 10 min at 2000 rpm at 4°C. The pellet was suspended in PBS 
and the washing step was repeated. The number of cells was adjusted to 2.5x105 /ml with PBS and 
30µL of cell suspension were mixed with 140 µL of 1% LMP agarose at 37°C. Twelve drops (10 µL) 
of agarose-cell suspension were placed on an NMP agarose coated slide using template provided on 
the metal base of the 12 gel chamber. Cells were lysed by placing the slides in 2.5 M NaCl, 0.1 M 
Na2EDTA, 10 mM Tris with 1% Triton X-100 pH 10 for 1 h at 4°C. The slides were placed in 
horizontal gel electrophoresis tank in electrophoresis solution (0.3 M NaOH, 0.001 M Na2EDTA) for 
20 min. Electrophoresis was carried out for 30 min at voltage gradient of 1V/cm across the platform at 
4° C. Neutralization of the slides was performed by washing them for 10 min in PBS in a staining jar 
at 4°C. Slides were than fixed by placing them in 70% ethanol for 10 min followed by 10 min 
incubation in absolute ethanol. DNA was stained by immersing the slides in a staining jar with SYBR 
Gold (Invitrogen) for 30 min in the dark. Staining solution was prepared according to the 
manufacturer’s instructions in 10 mM Tris, 1 mM EDTA buffer, pH 8. Stained slides were rinsed 
Page 28 of 33MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
23
 A
ug
us
t 2
01
8.
 D
ow
nl
oa
de
d 
by
 K
ar
ol
in
sk
a 
In
sti
tu
te
t U
ni
ve
rs
ity
 L
ib
ra
ry
 o
n 
8/
24
/2
01
8 
8:
16
:1
8 
A
M
. 
View Article Online
DOI: 10.1039/C8MD00316E
29 
 
twice with water and left to dry in the dark. Scoring of the comets was carried out using semi-
automated image analysis system (Comet Assay IV; Perceptive Instruments). On each gel 50 
nucleoids were analyzed and the results were expressed as percentage of tail intensity (% of DNA in 
tail). All experiments were performed in triplicate. PBS was used as negative control. The median % 
tail DNA for 50 comets was calculated for each of the duplicate gel in the experiments; the mean of 
the two median values was then calculated. The mean percentage of DNA in the tail is calculated 
from the independent triplicate experiments using Microsoft Excel software. 
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Hybrid 1,3,4-thiadiazole compounds containing catechol moiety with chalcone motif are 
synthesized and examined for antioxidant activity, cytotoxicity and DNA-binding activity. 
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